|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
Abstract |
|---|
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
|
|---|
The expression of the Bcl-2 family proteins Bax, Mcl-1, Bcl-2, and Bcl-xL, was examined in human peripheral blood eosinophils or in umbilical-cord-blood-derived eosinophils. Immunoblot analysis disclosed
high amounts of the proapoptotic factor Bax in freshly purified eosinophils of both types. Although cord-blood-derived eosinophils expressed easily detectable levels of Mcl-1, Bcl-2, and Bcl-xL, only traces or no
expression of these three antiapoptotic proteins were found in peripheral blood eosinophils. Incubation of
both eosinophil types for 1 to 3 days in a cytokine-deprived medium led to apoptosis, without changes in
the expression of Bax, Mcl-1, Bcl-2, or Bcl-xL. Although addition of interleukin-5 or interferon-
(IFN-)
to the culture medium increased the survival of both eosinophil types, a rise in the levels of Mcl-1 was observed only in IFN--treated cord-blood eosinophils. Together, these results indicate that human eosinophils have a specific profile of Bcl-2-family protein expression that depends on their maturation status and
may be modulated by stimuli that influence their survival.
| |
Introduction |
|---|
|
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
|
|---|
Increased numbers of eosinophils are frequently observed in blood and/or tissues in different diseases, including asthma, allergic rhinitis, atopic dermatitis, and the hypereosinophilic syndrome (1). Release by eosinophils of cytotoxic basic proteins, extracellular-matrix-degradation enzymes, lipid mediators, oxygen radicals, and inflammatory cytokines may contribute to the pathogenesis of these diseases (2). As recently proposed (3), blood and tissue eosinophilia may result at least in part from a defect in eosinophil apoptosis. This process has been extensively studied in a variety of cell types, leading to the discovery of different factors, such as the proapoptotic antigen Fas and its natural ligand, Fas-ligand (Fas-L) (4). Recent studies have shown that human blood eosinophils constitutively express a functional Fas antigen on their surface, since its stimulation induces their apoptotic death (5). The expression of Fas-L, however, was undetectable (8), suggesting that mechanisms unrelated to the Fas/Fas-L pathway may be involved in apoptosis observed upon the in vitro culture of human eosinophils in the absence of cytokines (5, 9). We therefore hypothezised that other factors, such as the pro- and antiapoptotic members of the Bcl-2 family, may play a role in this process.
The bcl-2 oncogene was isolated from the t(14;18) chromosomal breakpoint found in most cases of non-Hodgkin's B-cell lymphoma (10, 11), and was shown to encode
an intracellular protein that resides in the mitochondrial,
nuclear, and endoplasmic reticulum membranes (12, 13).
The first evidence for an effect of the Bcl-2 protein on cellular viability came from a study demonstrating that its
overexpression promotes survival in cytokine-deprived lymphoid and myeloid cell lines (14). In addition, Bcl-2
was shown to display inhibitory functions on cell death induced by chemotherapeutic drugs; c-Myc overexpression;
formation of reactive oxygen species; lipid peroxidation;
heat shock; UV- or -radiation; some viruses; and calcium,
azide, and glucose deprivation (15).
Recently, a family of genes with sequence similarities to bcl-2 has emerged (15). The bcl-x gene, isolated by low-stringency hybridization to bcl-2, encodes two distinct proteins: Bcl-xL, which increases cell viability as Bcl-2, and Bcl-xS, which shows opposite effects (16, 17). Bax protein was isolated by coimmunoprecipitation with Bcl-2 from a human B-cell line, and accelerates the death of cells in this line (18). Additionally, the mcl-1 gene was cloned in differentiated myeloid cells and shown to encode an antiapoptotic factor (19, 20).
The expression of these proteins depends on cell type,
as shown for Bcl-2, which is undetectable in neutrophils
but is present in T- and B-lymphocytes (21). Differentiation status may also influence the levels of Bcl-2, Bcl-xL or
Mcl-1 (16, 19, 21). Moreover, various stimuli that act
on apoptotic cell death, such as sphingosine; Ras activation; adhesion; cytokines including interleukin (IL)-2, IL-3,
IL-10, and tumor necrosis factor-
(TNF-); and cluster of
differentiation (CD)3, CD28 or CD40 activation, modulate the expression of these proteins (21, 24).
In the present study, the expression of Bcl-2, Bcl-xL,
Bcl-xS, Bax, and Mcl-1 was examined in terminally differentiated human peripheral blood eosinophils and in umbilical
cord blood eosinophils, which contain high proportions of
immature cells (32). Both eosinophil types were cultured in
cytokine-deprived medium, a condition leading to their
apoptosis (5, 9), or in the presence of IL-5 or interferon-
(IFN-), two cytokines known to prolong eosinophil survival and/or prevent eosinophil apoptosis (9, 33).
| |
Materials and Methods |
|---|
|
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
|
|---|
Reagents
Percoll and Ficoll-Paque were obtained from Pharmacia
(Orsay, France); Diff-Quik dye from Baxter Dade AG
(Duedingen, Switzerland); RPMI 1640 and fetal calf serum (FCS) from Gibco BRL (Cergy Pontoise, France); antibiotic-antimycotic solution and L-glutamine from Boehringer Mannheim (Meylan, France); prostaglandin E2 (PGE2), 2-mercaptoethanol, propidium iodide, naphthol AS-XM
phosphate, levamisole, Fast red salt TR, mouse anti-
actin monoclonal antibodies (mAb) (clone AC-74) from Sigma
(St. Quentin Fallavier, France); recombinant human IL-5
(rhIL-5) from Immugenex (Los Angeles, CA); mouse antihuman Bcl-2 mAb (clone 124), goat antimouse Ig, alkaline phosphatase antialkaline phosphatase (APAAP), murine
IgG1 isotype control, and fluorescein isothiocyanate (FITC)-
conjugated F(ab')2 fragment of goat antimouse Ig from
Dako (Trappes, France); rabbit antihuman Mcl-1 antibody
(Ab) from Pharmingen (San Diego, CA); peroxidase-conjugated sheep antimouse Ig, donkey antirabbit Ig, rainbow-protein markers, and ECL western blotting detection
system from Amersham (Les Ulis, France); and BioRad
protein assay reagent from BioRad (Munich, Germany).
Rabbit antihuman and antimouse Bax (N-20), and rabbit
antihuman and antimouse Bcl-xL/S (S-18) Abs were supplied by Tebu (Le Perray en Yvelines, France) for Santa
Cruz Biotechnology (Santa Cruz, CA). rhIL-3 was a kind
gift of Dr. U. K. Brown (Sandoz Biotechnology, Basel, Switzerland), and rhIFN- was provided by Dr. P. Devillier,
Roussel Uclaf (Romainville, France).
Eosinophil and Peripheral Blood Mononuclear Cell Preparations
Human peripheral venous blood from healthy donors (eosinophil counts ranging from 49 × 109/liter to 493 × 109/liter) was obtained from the Centre de Transfusion Sanguine (Paris, France) and used to purify eosinophils and peripheral blood mononuclear cells (PBMC). When indicated, eosinophils were isolated from individuals with blood hypereosinophilia (eosinophil counts ranging from 1,046 × 109/liter to 10,848 × 109/liter) of various etiologies (two with leukemia, one with a parasitic infection, and one with hypereosinophilic syndrome). These patients were taking no medication at the time of blood sampling. Informed consent was obtained from these donors.
After removal of the mononuclear cells, normodense eosinophils from healthy individuals were isolated with a 1.082 g/ml Percoll gradient, hypotonic lysis of erythrocytes, and depletion of neutrophils by the immunomagnetic method, as previously described (5). In the case of hypereosinophilic donors, a 1.077 g/ml Percoll gradient was used to isolate hypodense eosinophils. Viability (98.5 ± 0.3% and 97.6 ± 1.9% viable cells, n = 20 and n = 4, for normal and hypereosinophilic donors, respectively) and purity (98.6 ± 0.3% and 91.0 ± 6.1% normodense and hypodense eosinophils, n = 20 and n = 4, respectively) of the final cell suspension were evaluated by the trypan blue exclusion method and after staining of cytospin preparations with Diff-Quik dye, respectively.
To purify PBMC, blood was mixed with 3% dextran and allowed to settle at 20°C for 30 min. Buffy coat was next layered onto a Ficoll-Paque gradient. Expression of Bcl-2-family proteins was evaluated in freshly purified PBMC, which constitutively express high levels of Bcl-2, Bcl-xL, Bax, and Mcl-1 (21).
Eosinophils differentiated from umbilical cord blood cells were obtained as described (32). Briefly, umbilical cord blood was layered over Ficoll-Paque gradient. The mononuclear cell fraction was then cultured in RPMI 1640 medium supplemented with 0.3 µM PGE2, 50 µM 2-mercaptoethanol, and 10% FCS. Eosinophil differentiation was obtained by enriching the culture medium with 2 ng/ml rhIL-3 and 5 ng/ml rhIL-5. Washed cells were used after 3 wk of culture, the medium being replaced every week. Viability and purity of the final cell suspension were of 95.6 ± 1.1% viable cells and 89.1 ± 1.4% eosinophils (n = 16), respectively. Contaminant cells were mostly basophils (12.4 ± 2.8%, n = 16), as identified by toluidine blue staining.
Peripheral or umbilical cord blood eosinophils (1.5 × 106/ml) were resuspended in culture medium consisting of
RPMI 1640 supplemented with 1% antibiotic-antimycotic
solution, 10% FCS, and 2 mM L-glutamine, and were cultured in flat-bottom 12- or 96-well culture plates at 37°C in
a 5% CO2 atmosphere for 1 and 3 d, in the absence or presence of 5 ng/ml rhIL-5 or 1,000 U/ml rhIFN-.
Determination of Eosinophil Apoptosis by Flow Cytometry
Eosinophils (0.3 × 106) were resuspended in a solution containing 0.1% Triton X100, 0.1% sodium citrate, and 50 µg/ml propidium iodide, as described (34). Cells were applied to a FACScan flow cytometer (Becton Dickinson, Le Pont de Claix, France), and a total of 5,000 ungated cells were analyzed, using LYSIS software (Becton Dickinson). The percent of weakly propidium iodide-stained apoptotic nuclei was determined.
Evaluation of Bcl-2-family Protein Expression by Immunoblot Analysis
PBMC, peripheral blood eosinophils, or cord blood eosinophils were incubated for 10 min at 4°C with the lysis
buffer containing 0.2% NP-40, 50 mM NaCl, 10 mM 4-(2-hydroxyethyl)-1-piperazine-N'-2-ethanesulfonic acid (pH
8.0), 0.5 M sucrose, 1 mM EDTA disodium salt, 2 mM phenylmethylsulfonyl fluoride (PMSF), and 7 mM 2-mercaptoethanol, and were subsequently centrifuged for 15 min
at 12,000 × g. Supernatant was mixed with glycerol and
the protein content was determined with the BioRad protein assay. Aliquots containing 25 µg or 100 µg of total
proteins, or of rainbow-protein markers (14.3-200 kD) were
mixed with a 3× loading buffer consisting of 150 mM Tris
(pH 6.8), 300 mM dithiothreitol (DTT), 6% sodium dodecyl sulfate (SDS), 0.1% bromophenol blue, and 30% glycerol solution. Samples were boiled for 5 min and subjected to SDS-10% polyacrylamide gel electrophoresis (PAGE),
except for Mcl-1 detection, for which SDS-8.5% PAGE
was used. After migration in a 26 mM Tris (pH 8.3), 192 mM
glycine and 0.1% SDS buffer, size-fractionated proteins
were electroblotted onto nitrocellulose filters in a 26 mM
Tris (pH 8.3), 192 mM glycine, and 20% methanol buffer.
Blots were immediately incubated once at 20°C for 10 min, with a reaction buffer consisting of 20 mM Tris (pH 7.6),
140 mM NaCl, 0.1% Tween-20, and 5% nonfat evaporated
milk. The membrane was next reacted for 1 h at 20°C with
the anti-Bcl-2, anti-Bax, anti-Bcl-xL/S, or anti-Mcl-1 Abs at
1:250, 1:500, 1:100 and 1:1,000 dilutions, respectively. After
two washes lasting 10 min at 20°C each, peroxidase-conjugated antimouse or antirabbit Ig Abs, both at a 1:1,000
dilution, were applied to the blot for 1 h at 20°C. Immunoblots were again washed three times and were then incubated for 1 min with the ECL western blotting detection system. Films were exposed for 1 min or 40 min before being developed. -Actin detection was next performed on
each blot. In this case, the first and second Abs were applied to the membrane for 10 min at 1:4,000 and 1:2,000 dilutions, respectively, and the film was exposed for 15 to 30 s.
The anti-Bcl-xL/S Ab reacts with an identical epitope present in both Bcl-xL and Bcl-xS and thus allows distinction of these proteins through the relative sizes of their bands (~ 30 kD for Bcl-xL and ~ 21 kD for Bcl-xS; [17]).
The intensities of expression of Bcl-2, Bax, Bcl-xL/S, Mcl-1,
and -actin were quantified using a Masterscan densitometer and ZeroDscan software (both from Scanalytics, Billerica, MA). Results are expressed as a ratio of the OD
values of Bcl-2, Bax, Bcl-xL/S or Mcl-1 bands to the OD
values of the -actin bands.
Immunocytochemical and Flow-cytometric Detection of Bcl-2
Peripheral or cord-blood-derived eosinophils and PBMC
were cytocentrifuged (Hettich, Tuttlingen, Germany) on
glass slides, fixed in acetone for 10 min at 20°C, wrapped in
a plastic film, and kept at 
20°C until use. Antibodies were
diluted in a buffer (50 mM Tris, 150 mM NaCl, pH 7.6)
supplemented with 1% bovine serum albumin (BSA). Cells
were incubated for 1 h at 20°C with 6 µg/ml anti-Bcl-2 mAb
or murine IgG1 isotype control, followed by goat antimouse
Ig and APAAP, both at a 1:25 dilution. Substrate solution,
consisting of 0.48 mM naphthol AS-XM phosphate, 2%
dimethylformamide, 100 mM Tris (pH 8.2), 1.3 mM levamisole, and 194 mM Fast red salt TR, was applied for 30 min
at 20°C. A light hematoxylin counterstaining was next performed. Slides were washed twice for 10 min between each
step. The proportion of Bcl-2-positive cells was calculated after counting approximately 200 cells in randomly selected
fields.
For flow-cytometric detection of Bcl-2, peripheral or cord-blood-derived eosinophils and PBMC (0.4 × 106) were centrifuged and resuspended in 200 µl of phosphate buffered saline (PBS) (NaCl 140 mM, Na2HPO4 9.2 mM, NaH2PO4 1.3 mM, pH 7.4) containing 0.25% formaldehyde. After 30 min incubation at room temperature, 1 ml of PBS supplemented with 10% FCS was added. Cells were next centrifuged and the pellets were resuspended in 200 µl of PBS containing 10% FCS and 0.025% saponin. Antibodies were diluted in this buffer. After 10 min incubation at 4°C, cells were centrifuged and next incubated for 1 h at 4°C with 6 µg/ml anti-Bcl-2 mAb or murine IgG1 isotype control. Cells were washed twice in the PBS-FCS-saponin buffer and incubated for 1 h at 4°C with 20 µg/ml FITC-conjugated F(ab')2 fragment of goat antimouse Ig. Cells were then washed once in PBS-FCS buffer, centrifuged, resuspended in the same buffer, and immediately subjected to flow cytometry. A total of 5,000 ungated cells were analyzed using the LYSIS software.
Statistical Analysis
Results are expressed as mean ± SEM of the indicated number of experiments. One-way analysis of variance (ANOVA) was used to determine significance among the groups. If a significant variance was found, a Student's t test for unpaired or paired values was used to assess comparability between the means. A value of P < 0.05 was considered significant.
| |
Results |
|---|
|
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
|
|---|
Detection of Bcl-2-family Proteins in Freshly Purified Peripheral Blood Eosinophils
The expression of Bax, Bcl-2, Mcl-1, and BclxL/S by freshly
purified peripheral blood normodense eosinophils from
healthy donors was first examined through immunoblotting, and compared with that of PBMC, included as a positive control. Using similar experimental conditions (25 µg
proteins, 1 min film exposure time), we found high levels
of Bax in eosinophils and in unstimulated PBMC (Figure
1). By densitometry, we established that the intensity of
Bax expression was similar in both cell types, since OD Bax/ OD -actin values for eosinophils and PBMC were 1.4 ± 0.4 and 0.7 ± 0.2, respectively (n = 4 to 7, differences not
statistically significant). Unstimulated PBMC also contained
Bcl-xL and Mcl-1, but not Bcl-xS, even though amounts of
proteins (100 µg) and film exposure time (40 min) were
greater than those used for Bax detection (Figure 1). Under the same conditions, eosinophils failed to express Bcl-xL and Bcl-xS, and only traces of Mcl-1 were detected in
half of the eosinophil preparations (Figure 1). Similarly, although Bcl-2 was easily detectable in PBMC, only traces
of this protein were observed in four of eight eosinophil
samples, although high quantities (100 µg) of proteins
were loaded onto gels and exposure times lasted up to 40 min (Figure 1).
|
The expression of Bcl-2 was next analyzed with immunocytochemistry and flow cytometry. Only 1.0 ± 0.7% (n = 5) peripheral blood eosinophils expressed Bcl-2, as determined through immunocytochemistry (Figure 2), whereas practically all lymphocytes in PBMC preparations stained positively for this antigen (data not shown). No staining was shown in isotype control-treated cells (data not shown). Flow-cytometric analysis also failed to demonstrate the presence of Bcl-2 in human blood eosinophils, in contrast to PBMC, which showed a marked expression of this protein (Figure 3).
|
|
The expression of Bcl-2 was further examined in freshly purified hypodense eosinophils obtained from hypereosinophilic donors. As with normodense blood eosinophils from healthy individuals, these cells failed to express Bcl-2, as determined by immunoblot and immunocytochemical analysis (data not shown).
Detection of Bcl-2-family Proteins in Umbilical-Cord-Blood-derived Eosinophils
We next analyzed the expression of Bcl-2-family proteins
in eosinophils obtained by culture of umbilical-cord-blood-derived mononuclear cells for 3 wk in the presence of 2 ng/ml
rhIL-3 and 5 ng/ml rhIL-5. As shown for peripheral blood
eosinophils, these cells did not contain Bcl-xS, and expressed high levels of Bax (Figure 4). However, cord blood-derived cells expressed amounts of Bcl-2 and Bcl-xL similar to those of PBMC (Figure 4). Indeed, OD Bcl-2/OD
-actin values for cord blood-derived eosinophils and
PBMC were 1.0 ± 0.3 and 2.1 ± 1.0, respectively, and OD
Bcl-xL/OD -actin values were 2.2 ± 0.5 and 3.4 ± 1.7, respectively (n = 4 to 6). Mcl-1 was also detectable in cord-blood-derived eosinophils, although wide variability in the
intensities of its basal expression was observed in the different cell preparations (OD Mcl-1/OD -actin produced
values of 0.0 to 17.3, n = 6). This phenomenon was unrelated to the purity of the cell samples (percent eosinophils
versus OD Mcl-1/OD -actin values: r = 0.645, P > 0.1, n = 6; percent basophils versus OD Mcl-1/OD -actin: r = 0.336, P > 0.1, n = 6).
|
Immunocytochemical analysis showed that 34.6 ± 4.6% of umbilical-cord-blood-derived cells were Bcl-2 positive (n = 9; Figure 2), a finding confirmed by flow cytometry (Figure 3).
Time- and Cytokine-dependent Modulation of Apoptosis and Expression of Bcl-2-family Proteins
Normodense peripheral or umbilical-cord-blood-derived
eosinophils were cultured for 1 or 3 d in the absence or in
the presence of 5 ng/ml rhIL-5 or 1,000 U/ml IFN-, and
the number of apoptotic nuclei was assessed through flow
cytometry.
Incubation of normodense peripheral or umbilical-cord-blood eosinophils for 1 or 3 days in a cytokine-deprived
medium resulted in an increase in the number of apoptotic
nuclei (Table 1). This phenomenon was unaccompanied
by changes in the expression of Bax, Bcl-2, Bcl-xL/S, Mcl-1,
or -actin (Figures 1, 4, and 5). However, a slight decrease
in the expression of Bcl-xL was observed in cord-blood-
derived eosinophils at Day 1, since the OD Bcl-xL/OD -actin values at Days 0 and 1 were 2.2 ± 0.5 and 1.3 ± 0.1, respectively (n = 6, differences not statistically significant).
|
|
When rhIL-5 or rhIFN- was added to the culture medium, a reduction in apoptotic death of peripheral blood
eosinophils was observed, the effect of both cytokines being less pronounced in cord-blood-derived cells (Table ).
These phenomena were unaccompanied by changes in the
expression of Bax, Bcl-2, Bcl-xL/S, or -actin in either eosinophil type (Figure 1). In contrast, a clear increase in Mcl-1
expression was observed at Days 1 and 3 in rhIFN--treated cord-blood eosinophils exclusively (Figures 1, 3, and 5).
No modifications in the expression of this protein were
found in rhIL-5-treated cells from either origin (Figures 1,
3, and 5).
| |
Discussion |
|---|
|
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
|
|---|
In this study, we examined the presence of Bax, Bcl-2, Bcl-xL and Bcl-xS, and Mcl-1 in human eosinophils. We showed that normodense eosinophils isolated from the blood of healthy individuals express constitutively high levels of the proapoptotic factor Bax, and practically no or only traces of the cell-death repressors Bcl-2, Bcl-xL, and Mcl-1. Bcl-xS, which positively regulates programmed cell death, was also undetectable. The pattern of Bcl-2-family protein expression that we found resembles that reported for neutrophils, but was very different from that observed in PBMC, since these cells constitutively express Bcl-2, Bcl-xL, Mcl-1, and Bax, but not Bcl-xS (21). The tendency of mature eosinophils, like neutrophils, to express high quantities of the proapoptotic factor Bax and low amounts of the anti-cell-death proteins Bcl-2, Bcl-xL, and Mcl-1 may reflect their short life span in vitro (35). These results, however, are not compatible with the slower rate of in vitro eosinophil as opposed to neutrophil apoptosis (35). This suggests that other factors belonging to the Bcl-2 family and with anti-cell-death properties may be expressed by eosinophils and may be involved in their spontaneous apoptosis. Accordingly, the A1, bfl-1, and bcl-w genes have been shown to encode proteins with sequence homologies to Bcl-2 (36- 38). Overexpression of the A1 protein delays apoptosis after cytokine deprivation in a murine IL-3-dependent cell line (39), and its gene was recently cloned in cultured human endothelial cells (36). Enforced expression of bcl-w, a gene highly conserved between the mouse and human, renders murine lymphoid and myeloid cells refractory to several cytotoxic treatments (37), whereas bfl-1 suppresses p53-induced apoptosis in rodent epithelial cells (38, 40). Lack of specific reagents for detecting A1, Bfl-1, or Bcl-w proteins prevented the analysis of their expression in this study.
As discussed earlier, previous studies failed to detect
Bcl-2 in mature neutrophils, whereas its presence at high
levels was reported in their bone-marrow precursors (22).
Since a decrease in Bcl-2, Mcl-1 and Bcl-xL expression has
also been described during T-cell maturation in vivo (16,
21, 23), we postulated that the differentiation status of
eosinophils might also influence the expression of Bcl-2-family proteins. We therefore examined the level of these
proteins in umbilical-cord-blood-derived eosinophils, which
have been previously defined as immature cells (32). Interestingly, these eosinophils exhibit a pattern of Bcl-2-family
protein expression similar to that found in unstimulated
PBMC, since they contain constitutively high amounts of
Bcl-2, Bcl-xL, and Bax, and detectable levels of Mcl-1, but
not of Bcl-xS. However, since immature eosinophils were
obtained after 3 wk of culture of hematopoietic precursors in the presence of IL-3 and IL-5, the hypothesis may be
raised that the difference in the profile of expression of the
Bcl-2-family proteins would be linked to their activation
by long-term exposure to these cytokines. Our observations that: (1) neither IL-5 nor IFN- modified the levels
of Bcl-2, Bcl-xL, or Mcl-1 in peripheral blood eosinophils
from healthy donors, and that: (2) hypodense eosinophils
from hypereosinophilic individuals, considered to be in
vivo-activated cells (2), failed to express Bcl-2 in a manner
similar to that of normodense blood eosinophils, may exclude this possibility.
Culture of peripheral or cord-blood eosinophils in the absence of cytokines induced a time-dependent increase in their apoptosis, confirming previous reports (5, 9). Spontaneous apoptotic death in both eosinophil types was unaccompanied by changes in the levels of Bcl-2, Mcl-1, Bcl-xL, or Bax, indicating that these events might be unrelated. Although the constitutive pattern of Bcl-2-family protein expression was different for peripheral and umbilical-cord-blood-derived eosinophils, the kinetics and the degree of their apoptosis were similar. These findings suggest that the discrepancy in the profiles of Bcl-2-family protein expression by these two eosinophil types is not predictive of the evolution of cell survival, but may reflect a potential difference in the sensitivity to apoptotic stimuli, as shown for other cell types (15). Alternatively, additional mechanisms may be implicated in eosinophil death, including the expression of other pro- (41) or antiapoptotic (36) members of the Bcl-2 family, and/or of factors unrelated to this family. Among these molecules, the intracellular IL-1-converting enzyme-like proteases are claimed to play a critical role in controlling apoptotic death in different cell types (44). Whether these molecules also participate actively in the regulation of eosinophil apoptosis is an area for further investigation.
Our findings also extend those in previous studies,
showing that IL-5 and IFN- prolonged the survival of peripheral and umbilical-cord-blood eosinophils (9, 33). Previous studies have shown that inhibition of eosinophil apoptosis by IL-5 depends on the synthesis of new proteins (9).
The members of the Bcl-2 family may be good candidates for such proteins, since induction of Bcl-2 expression has
been observed in an erythroleukemic cell line upon culture
with IL-3 (27). However, no modifications in the expression of the Bcl-2-family proteins were found when both
eosinophil types were incubated with IL-5. In contrast,
IFN- may modulate cord, but not peripheral, blood eosinophil apoptosis by augmenting the levels of Mcl-1.
In conclusion, our findings demonstrate that Bcl-2, Bcl-xL,
Mcl-1, and Bax are expressed constitutively by umbilical-cord-blood eosinophils, and that the expression of some of
these proteins probably decreases during cell maturation,
as suggested for neutrophils and T- and B-lymphocytes
(16, 21). The expression of Mcl-1 is augmented by IFN-,
indicating that this member of the Bcl-2 family may represent a novel target for other stimuli that influence eosinophil survival.
| |
Footnotes |
|---|
Abbreviations: antibody, Ab; alkaline phosphatase-antialkaline phosphatase, APAAP; cluster of differentiation, CD; Fas-ligand, Fas-L; peripheral blood mononuclear cells, PBMC.
(Received in original form May 8, 1997).
Acknowledgments: This work was supported by Grant 1388 from the Association pour la Recherche sur le Cancer, Paris, France. The authors are grateful to Dr. Nicole Israël and Ms. Fabienne Aillet (Unité de Biologie des Rétrovirus, Institut Pasteur, Paris, France) for help in performing initial immunoblot assays, and to the nurses of the Maternité du Centre Hospitalier Universitaire Pitié-Salpétrière (Paris, France) for providing umbilical cord blood.
| |
References |
|---|
|
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
|
|---|
1. Butterfield, J. H., and K. M. Leiferman. 1993. Eosinophil-associated diseases. In The Handbook of Immunopharmacology: Immunopharmacology of eosinophils. H. Smith and R. M. Cook, editors. Academic Press Limited, London. 151-192.
2. Kroegel, C., J.-C. Virchow Jr., W. Luttmann, C. Walker, and J. A. Warner. 1994. Pulmonary immune cells in health and disease: the eosinophil leukocyte (Part I). Eur. Respir. J. 7: 519-543 [Abstract].
3. Simon, H.-U., and K. Blaser. 1995. Inhibition of programmed eosinophil death: a key pathogenic event for eosinophilia? Immunol. Today 16: 53-55 [Medline].
4. Mountz, J. D., T. Zhou, J. Wu, W. Wang, X. Su, and J. Cheng. 1995. Regulation of apoptosis in immune cells. J. Clin. Immunol. 15: 1-16 [Medline].
5.
Druilhe, A.,
Z. Cai,
S. Hailé,
S. Chouaib, and
M. Pretolani.
1996.
Fas-mediated apoptosis in cultured human eosinophils.
Blood
87:
2822-2830
6.
Matsumoto, K.,
R. P. Schleimer,
H. Saito,
Y. Iikura, and
B. S. Bochner.
1995.
Induction of apoptosis in human eosinophils by anti-Fas antibody
treatment in vitro.
Blood
86:
1437-1443
7. Hebestreit, H., S. Yousefi, I. Balatti, M. Weber, R. Crameri, D. Simon, K. Hartung, A. Schapowal, K. Blaser, and H.-U. Simon. 1996. Expression and function of the Fas receptor on human blood and tissue eosinophils. Eur. J. Immunol. 26: 1775-1780 [Medline].
8.
Liles, W. C.,
P. A. Kiener,
J. A. Ledbetter,
A. Aruffo, and
S. J. Klebanoff.
1996.
Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils.
J. Exp. Med.
184:
429-440
9.
Yamaguchi, Y.,
T. Suda,
S. Ohta,
K. Tominaga,
Y. Miura, and
T. Kasahara.
1991.
Analysis of the survival of mature human eosinophils: interleukin-5
prevents apoptosis in mature human eosinophils.
Blood
78:
2542-2547
10.
Tsujimoto, Y.,
J. Cossman,
E. Jaffe, and
C. M. Croce.
1985.
Involvement of
the bcl-2 gene in human follicular lymphoma.
Science
228:
1440-1443
11.
Tsujimoto, Y., and
C. M. Croce.
1986.
Analysis of the structure, transcripts,
and protein products of bcl-2, the gene involved in human follicular lymphoma.
Proc. Natl. Acad. Sci. USA
83:
5214-5218
12. Hockenberry, D., G. Nuñez, C. Milliman, R. D. Schreiber, and S. J. Korsmeyer. 1990. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348: 334-336 [Medline].
13.
Krajewski, S.,
S. Tanaka,
S. Takayama,
M. J. Schibler,
W. Fenton, and
J. C. Reed.
1993.
Investigation of the subcellular distribution of the Bcl-2 oncoprotein: residence in the nuclear enveloppe, endoplasmic reticulum, and
outer mitochondrial membranes.
Cancer Res.
53:
4701-4714
14. Vaux, D. L., S. Cory, and J. Adams. 1988. Bcl-2 gene promotes haematopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 355: 440-442 .
15.
Reed, J. C..
1994.
Bcl-2 and the regulation of programmed cell death.
J. Cell
Biol.
124:
1-6
16. Boise, L. H., M. Gonzalez-Garcia, C. E. Postema, L. Ding, T. Lindsten, L. A. Turka, X. Mao, G. Nuñez, and C. B. Thompson. 1993. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74: 597-608 [Medline].
17.
Minn, A. J.,
L. H. Boise, and
C. B. Thompson.
1996.
Bcl-xS antagonizes the
effects of Bcl-xL.
J. Biol. Chem.
271:
6306-6312
18. Oltvai, Z. N., C. L. Milliman, and S. J. Korsmeyer. 1993. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74: 609-619 [Medline].
19.
Kozopas, K. M.,
T. Yang,
H. L. Buchan,
P. Zhou, and
R. W. Craig.
1993.
Mcl-1, a gene expressed in programmed myeloid cell differentiation, has
sequence similarity to bcl-2.
Proc. Natl. Acad. Sci. USA
90:
3516-3520
20.
Reynolds, J. E.,
J. D. Jenkinson,
P. Zhou,
L. P. Zhou,
A. Eastman, and
R. W. K. Craig.
1994.
Mcl-1, a member of the bcl-2 gene family, delays
apoptosis induced by c-Myc overexpression in CHO cells.
Cancer Res.
54:
6348-6352
21.
Ohta, K.,
K. Iwai,
Y. Kasahara,
N. Taniguchi,
S. Krajewski,
J. C. Reed, and
T. Miyawaki.
1995.
Immunoblot analysis of cellular expression of Bcl-2
family proteins, Bcl-2, Bax, Bcl-x and Mcl-1, in human peripheral blood
and lymphoid tissues.
Int. Immunol.
7:
1817-1825
22. Digiuseppe, J. A., P. Lebeau, J. Augenbraun, and M. J. Borowitz. 1996. Multiparameter flow cytometric analysis of Bcl-2 and Fas expression in normal and neoplastic hematopoiesis. Am. J. Clin. Pathol. 106: 345-351 [Medline].
23. Gratiot-Deans, J., R. Merino, G. Nuñez, and L. A. Turka. 1994. Bcl-2 expression during T cell development: early loss and late return occur at specific stages of commitment to differentiation. Proc. Natl. Acad. Sci. USA 9: 10685-10689 .
24. Sakakura, C., E. A. Sweeney, T. Shirahama, S.-I. Hakomori, and Y. Igarashi. 1996. Suppression of bcl-2 gene expression by sphingosine in the apoptosis of human leukemic HL-60 cells during phorbol ester-induced terminal differentiation. FEBS Lett. 379: 177-180 [Medline].
25. Kinoshita, T., T. Yokota, K. I. Arai, and A. Miyajima. 1995. Regulation of Bcl-2 expression by oncogenic Ras protein in hematopoietic cells. Oncogene 10: 2207-2212 [Medline].
26.
Zhang, Z.,
K. Vuori,
J. C. Reed, and
E. Ruoslahti.
1995.
The 51 integrin
supports survival of cells on fibronectin and up-regulates Bcl-2 expression.
Proc. Natl. Acad. Sci. USA
92:
6161-6165
27.
Rinaudo, M. S.,
K. Su,
L. A. Falk,
S. Haldar, and
R. A. Mufson.
1995.
Human interleukin-3 receptor modulates bcl-2 mRNA and protein levels
through protein kinase C in TF-1 cells.
Blood
86:
80-88
28. Levy, Y., and J. C. Brouet. 1994. Interleukin-10 prevents spontaneous death of germinal center B cells by induction of the Bcl-2 protein. J. Clin. Invest. 93: 424-428 .
29.
Genestier, L.,
N. Bonnefoy-Berard,
J.-P. Rouault,
M. Flacher, and
J.-P. Revillard.
1995.
Tumor necrosis factor- up-regulates Bcl-2 expression and
decreases calcium-dependent apoptosis in human B cell lines.
Int. Immunol.
7:
533-540
30. Mueller, D. L., S. Seiffert, W. Fang, and T. W. Behrens. 1996. Differential regulation of Bcl-2 and Bcl-x by CD3, CD28, and the IL-2 receptor in cloned CD4+ helper T cells: a model for the long-term survival of memory cells. J. Immunol. 156: 1764-1771 [Abstract].
31. Choi, M. S. K., L. H. Boise, A. R. Gottschalk, J. Quintans, C. B. Thompson, and G. G. B. Klaus. 1995. The role of Bcl-xL in CD40-mediated rescue from anti-µ-induced apoptosis in WEHI-231 B lymphoma cells. Eur. J. Immunol. 25: 1352-1357 [Medline].
32.
Saito, H.,
K. Hatake,
A. M. Dvorak,
K. M. Leiferman,
A. M. Donnenberg,
N. Arai,
K. Ishizaka, and
T. Ishizaka.
1988.
Selective differentiation and
proliferation of hematopoietic cells induced by recombinant human interleukins.
Proc. Natl. Acad. Sci. USA
85:
2288-2292
33. Valerius, T., R. Repp, J. R. Kalden, and E. Platzer. 1990. Effects of IFN on human eosinophils in comparison with other cytokines: a novel class of eosinophil activators with delayed onset of action. J. Immunol. 145: 2950-2958 [Abstract].
34. Nicoletti, I., G. Migliorati, M. C. Pagliacci, F. Grignani, and C. Riccardi. 1991. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Methods 139: 271-279 [Medline].
35. Stern, M., L. Meagher, J. Savill, and C. Haslett. 1992. Apoptosis in human eosinophils: programmed cell death in the eosinophil leads to phagocytosis by macrophages and is modulated by IL-5. J. Immunol. 148: 3543-3549 [Abstract].
36.
Karsan, A.,
E. Yee,
K. Kaushansky, and
J. Harlan.
1996.
Cloning of a human Bcl-2 homologue: inflammatory cytokines induce human A1 in cultured endothelial cells.
Blood
87:
3089-3096
37. Gibson, L., S. P. Holmgreen, D. C. S. Huang, O. Bernard, N. G. Copeland, N. A. Jenkins, G. R. Sutherland, E. Baker, J. M. Adams, and S. Cory. 1996. bcl-w, a novel member of the Bcl-2 family, promotes cell survival. Oncogene 13: 665-675 [Medline].
38.
D'Sa-Eipper, C.,
T. Subramanian, and
G. Chinnadurai.
1996.
Bfl-1, a Bcl-2
homologue, suppresses p53-induced apoptosis and exhibits potent cooperative transforming activity.
Cancer Res.
56:
3879-3882
39.
Lin, E. Y.,
A. Orlofsky,
H.-G. Wang,
J. C. Reed, and
M. B. Prystowsky.
1996.
A1, a Bcl-2 family member, prolongs cell survival and permits myeloid differentiation.
Blood
87:
983-992
40. Choi, S. S., I.-C. Park, J. W. Yun, Y. C. Sung, S. I. Hong, and H.-S. Shin. 1995. A novel bcl-2 related gene, bfl-1, is overexpressed in stomach cancer and preferentially expressed in bone marrow. Oncogene 11: 1693-1698 [Medline].
41. Yang, E., J. Zha, J. Jockel, L. H. Boise, C. B. Thompson, and S. J. Korsmeyer. 1995. Bad, a heterodimeric partner for Bcl-xL and Bcl-2, displaces Bax and promotes cell death. Cell 80: 285-291 [Medline].
42. Boyd, J. M., G. J. Gallo, B. Elangovan, A. B. Houghton, S. Malstrom, B. J. Avery, R. J. Ebb, T. Subramanian, T. Chittenden, R. J. Lutz, and G. Chinnadurai. 1995. Bik, a novel death inducing protein shares a distinct sequence motif with Bcl-2 family proteins and interacts with viral and cellular survival-promoting proteins. Oncogene 11: 1921-1928 [Medline].
43. Farrow, S. N., J. H. M. White, I. Martinou, T. Raven, K.-T. Pun, C. J. Grinham, J.-C. Martinou, and R. Brown. 1995. Cloning of a Bcl-2 homologue by interaction with adenovirus E1B19K. Nature 374: 731-733 [Medline].
44. Patel, T., G. J. Gores, and S. C. Kaufmann. 1996. The role of proteases during apoptosis. FASEB J. 10: 587-597 [Abstract].
This article has been cited by other articles:
 |
|
 |
|
  J. J. Smit, L. Boon, and N. W. Lukacs Respiratory Virus-Induced Regulation of Asthma-Like Responses in Mice Depends upon CD8 T Cells and Interferon-{gamma} Production Am. J. Pathol., December 1, 2007; 171(6): 1944 - 1951. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Dolgachev, M. Thomas, A. Berlin, and N. W. Lukacs Stem cell factor-mediated activation pathways promote murine eosinophil CCL6 production and survival J. Leukoc. Biol., April 1, 2007; 81(4): 1111 - 1119. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Rosas, P. F. Dijkers, C. L. Lindemans, J.-W. J. Lammers, L. Koenderman, and P. J. Coffer IL-5-mediated eosinophil survival requires inhibition of GSK-3 and correlates with {beta}-catenin relocalization J. Leukoc. Biol., July 1, 2006; 80(1): 186 - 195. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Sly, S. M. Hingley-Wilson, N. E. Reiner, and W. R. McMaster Survival of Mycobacterium tuberculosis in Host Macrophages Involves Resistance to Apoptosis Dependent upon Induction of Antiapoptotic Bcl-2 Family Member Mcl-1 J. Immunol., January 1, 2003; 170(1): 430 - 437. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Gardai, R. Hoontrakoon, C. D. Goddard, B. J. Day, L. Y. Chang, P. M. Henson, and D. L. Bratton Oxidant-Mediated Mitochondrial Injury in Eosinophil Apoptosis: Enhancement by Glucocorticoids and Inhibition by Granulocyte-Macrophage Colony-Stimulating Factor J. Immunol., January 1, 2003; 170(1): 556 - 566. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Letuve, A. Druilhe, M. Grandsaigne, M. Aubier, and M. Pretolani Critical Role of Mitochondria, but Not Caspases, during Glucocorticosteroid-Induced Human Eosinophil Apoptosis Am. J. Respir. Cell Mol. Biol., May 1, 2002; 26(5): 565 - 571. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G. Zangrilli Regulation of Eosinophil Viability by Cytokines Am. J. Respir. Cell Mol. Biol., April 1, 2002; 26(4): 388 - 390. [Full Text] [PDF]
|
|
|
|
|
|
R. Hoontrakoon, H. W. Chu, S. J. Gardai, S. E. Wenzel, P. McDonald, V. A. Fadok, P. M. Henson, and D. L. Bratton Interleukin-15 Inhibits Spontaneous Apoptosis in Human Eosinophils via Autocrine Production of Granulocyte Macrophage-Colony Stimulating Factor and Nuclear Factor-kappa B Activation Am. J. Respir. Cell Mol. Biol., April 1, 2002; 26(4): 404 - 412. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Letuve, A. Druilhe, M. Grandsaigne, M. Aubier, and M. Pretolani Involvement of caspases and of mitochondria in Fas ligation-induced eosinophil apoptosis: modulation by interleukin-5 and interferon-{gamma} J. Leukoc. Biol., November 1, 2001; 70(5): 767 - 775. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Temple, E. Allen, J. Fordham, S. Phipps, H.-C. Schneider, K. Lindauer, I. Hayes, J. Lockey, K. Pollock, and R. Jupp Microarray Analysis of Eosinophils Reveals a Number of Candidate Survival and Apoptosis Genes Am. J. Respir. Cell Mol. Biol., October 1, 2001; 25(4): 425 - 433. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Dewson, G. M. Cohen, and A. J. Wardlaw Interleukin-5 inhibits translocation of Bax to the mitochondria, cytochrome c release, and activation of caspases in human eosinophils Blood, October 1, 2001; 98(7): 2239 - 2247. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-M. Huang, C.-J. Huang, and J. J.-Y. Yen Mcl-1 is a common target of stem cell factor and interleukin-5 for apoptosis prevention activity via MEK/MAPK and PI-3K/Akt pathways Blood, September 1, 2000; 96(5): 1764 - 1771. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Leuenroth, P. S. Grutkoski, A. Ayala, and H. H. Simms The loss of Mcl-1 expression in human polymorphonuclear leukocytes promotes apoptosis J. Leukoc. Biol., July 1, 2000; 68(1): 158 - 166. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. A. Giembycz and M. A. Lindsay Pharmacology of the Eosinophil Pharmacol. Rev., June 1, 1999; 51(2): 213 - 340. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Dewson, G. M. Walsh, and A. J. Wardlaw Expression of Bcl-2 and Its Homologues in Human Eosinophils . Modulation by Interleukin-5 Am. J. Respir. Cell Mol. Biol., April 1, 1999; 20(4): 720 - 728. [Abstract] [Full Text]
|
|
|
|
|
|
A. Druilhe, B. Wallaert, A. Tsicopoulos, J.-R. L. e Silva, I. Tillie-Leblond, A.-B. Tonnel, and M. Pretolani Apoptosis, Proliferation, and Expression of Bcl-2, Fas, and Fas Ligand in Bronchial Biopsies from Asthmatics Am. J. Respir. Cell Mol. Biol., November 1, 1998; 19(5): 747 - 757. [Abstract] [Full Text]
|
|
|
|
|
|
B. Dibbert, I. Daigle, D. Braun, C. Schranz, M. Weber, K. Blaser, U. Zangemeister-Wittke, A. N. Akbar, and H.-U. Simon Role for Bcl-xL in Delayed Eosinophil Apoptosis Mediated by Granulocyte-Macrophage Colony-Stimulating Factor and Interleukin-5 Blood, August 1, 1998; 92(3): 778 - 783. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. D. Bingle, R. W. Craig, B. M. Swales, V. Singleton, P. Zhou, and M. K. B. Whyte Exon Skipping in Mcl-1 Results in a Bcl-2 Homology Domain 3 Only Gene Product That Promotes Cell Death J. Biol. Chem., July 14, 2000; 275(29): 22136 - 22146. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Proc. Am. Thorac. Soc. | Am. J. Respir. Crit. Care Med. |